Natera, Inc. (NASDAQ:NTRA) CEO Sells $206,378.84 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,709 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84. Following the sale, the chief executive officer now directly owns 194,615 shares of the company’s stock, valued at approximately $23,501,707.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $419,712.68.

Natera Price Performance

Shares of NASDAQ NTRA opened at $119.17 on Friday. The stock has a market capitalization of $14.74 billion, a price-to-earnings ratio of -48.64 and a beta of 1.53. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $133.54. The firm’s 50 day simple moving average is $123.37 and its 200-day simple moving average is $111.09. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the firm posted ($0.97) EPS. The business’s revenue was up 58.1% on a year-over-year basis. Analysts expect that Natera, Inc. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. BTIG Research upped their price objective on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. UBS Group cut their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Friday. Finally, Morgan Stanley increased their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $124.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quent Capital LLC lifted its position in shares of Natera by 3.2% during the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after buying an additional 99 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after purchasing an additional 135 shares in the last quarter. Private Advisor Group LLC lifted its holdings in Natera by 5.2% in the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after purchasing an additional 135 shares in the last quarter. Finally, Lake Street Advisors Group LLC lifted its holdings in Natera by 7.4% in the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 156 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.